Changes in immune profiles and platelet function after start TPO-RA in ITP

Prospective multicenter cohort for evaluation of changes in Immune profile and platelet function after start of TPO-receptor agonist in patients with ITP

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON28113

Enrollment

Registered

2020-05-12

Start date

2019-08-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune thrombocytopenia (ITP)

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - Age 16 years and older - Previously confirmed diagnosis of primary ITP with current platelet counts of <100x109/L - Will start treatment with eltrombopag - Willing and be able to understand the study information and sign the informed consent form.

Exclusion criteria

Exclusion criteria: - Documented history of persisting severe anemia (defined as hemoglobin <6.0 mmol/L for men and women) - Treatment with rituximab in the past 9 months - Treatment with any immune modulating drug other than corticosteroids in the past 3 months

Design outcomes

Primary

Measure	Time frame
Change in immunologic profile and platelet function before start and during treatment with eltrombopag	—

Secondary

Measure	Time frame
Difference in immunologic profile or platelet function at baseline between responding and non-responding patients	—

Contacts

Public ContactWobke van Dijk

UMC Utrecht

w.e.m.vandijk-16@umcutrecht.nl08875678946

Outcome results